Soligenix Inc (SNGX) Stock Price, Quote & News

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 538 8200

Fax: 609 452 6467

Website: www.soligenix.com

Address:

29 Emmons Drive, Suite B-10, Princeton, United States

PaulLaurent May. 2 at 7:05 PM

📉🔻 Top Losers 🔻📉Last Week $AREB $CHSN $SNGX $HUBC $SDOT

0 · Reply

Vladxccc May. 1 at 3:27 PM

$SNGX 5000 shares at .34 , f**k it why not

0 · Reply

GreedyGopher May. 1 at 1:27 PM

$SNGX In the last 5 years, this company which has never brought ANYTHING to market, is down 99.91% The CEO is still highly compensated although all of his investors have lost everything.......time to pull the plug on thus turd of a company.

0 · Reply

Sngxscam May. 1 at 10:56 AM

$SNGX Decieve delay dilute.

0 · Reply

debbiekatz May. 1 at 6:05 AM

$SNGX .34-.35 worth a shot

0 · Reply

Vote4Pedro2 May. 1 at 12:36 AM

$SNGX

0 · Reply

mrjamesgriffith Apr. 30 at 7:42 PM

$SNGX $AREB time to buy it hold it and double it. Opportunity favors those who are open to risk and volatility. Money comes in and leaves like waves in the ocean 🌊 high tide is coming don't sell because you can't see the incoming wave. Hold and relax.

0 · Reply

SpencerF Apr. 30 at 1:38 AM

$SNGX glad I finally dumped this yesterday. Any reason to pick some back up as it continues down? Or is company pretty much confirmed done?

2 · Reply

ieatbaguette Apr. 29 at 7:45 PM

$SNGX

0 · Reply

mike537 Apr. 29 at 7:31 PM

$SNGX what a piece of 💩

0 · Reply

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Apr 2, 2026, 7:30 AM EDT - 4 weeks ago

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Mar 31, 2026, 7:30 AM EDT - 4 weeks ago

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Mar 26, 2026, 7:30 AM EDT - 5 weeks ago

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Mar 23, 2026, 7:30 AM EDT - 5 weeks ago

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

Mar 19, 2026, 8:00 AM EDT - 6 weeks ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.

Mar 19, 2026, 7:30 AM EDT - 6 weeks ago

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

Mar 10, 2026, 7:30 AM EDT - 7 weeks ago

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

Feb 26, 2026, 7:30 AM EST - 2 months ago

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Feb 24, 2026, 7:30 AM EST - 2 months ago

Soligenix to Present at BIO Investment & Growth Summit

Feb 12, 2026, 7:30 AM EST - 2 months ago

Soligenix Details Recent Progress and Upcoming Milestones

Dec 18, 2025, 7:30 AM EST - 4 months ago

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Dec 17, 2025, 1:23 PM EST - 4 months ago

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Dec 17, 2025, 7:30 AM EST - 4 months ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Dec 3, 2025, 8:30 AM EST - 5 months ago

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

Nov 19, 2025, 7:30 AM EST - 5 months ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 7, 2025, 7:30 AM EST - 6 months ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Oct 14, 2025, 7:30 AM EDT - 7 months ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Oct 7, 2025, 7:30 AM EDT - 7 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Sep 30, 2025, 7:30 AM EDT - 7 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 29, 2025, 4:05 PM EDT - 7 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 7 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 23, 2025, 7:30 AM EDT - 7 months ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Sep 4, 2025, 7:30 AM EDT - 8 months ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 2, 2025, 7:30 AM EDT - 8 months ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 1:03 PM EDT - 9 months ago

Why Is Soligenix Stock Soaring On Monday?

Aug 18, 2025, 7:30 AM EDT - 9 months ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 14, 2025, 7:30 AM EDT - 9 months ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

Aug 8, 2025, 8:30 AM EDT - 9 months ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Jul 31, 2025, 7:30 AM EDT - 9 months ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 8, 2025, 7:30 AM EDT - 10 months ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 1, 2025, 7:30 AM EDT - 10 months ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jun 6, 2025, 9:37 AM EDT - 11 months ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

May 9, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Mar 25, 2025, 8:30 AM EDT - 1 year ago

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 21, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 6, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at Upcoming Investor Conferences

PaulLaurent May. 2 at 7:05 PM

📉🔻 Top Losers 🔻📉Last Week $AREB $CHSN $SNGX $HUBC $SDOT

0 · Reply

Vladxccc May. 1 at 3:27 PM

$SNGX 5000 shares at .34 , f**k it why not

0 · Reply

GreedyGopher May. 1 at 1:27 PM

0 · Reply

Sngxscam May. 1 at 10:56 AM

$SNGX Decieve delay dilute.

0 · Reply

debbiekatz May. 1 at 6:05 AM

$SNGX .34-.35 worth a shot

0 · Reply

Vote4Pedro2 May. 1 at 12:36 AM

$SNGX

0 · Reply

mrjamesgriffith Apr. 30 at 7:42 PM

0 · Reply

SpencerF Apr. 30 at 1:38 AM

$SNGX glad I finally dumped this yesterday. Any reason to pick some back up as it continues down? Or is company pretty much confirmed done?

2 · Reply

ieatbaguette Apr. 29 at 7:45 PM

$SNGX

0 · Reply

mike537 Apr. 29 at 7:31 PM

$SNGX what a piece of 💩

0 · Reply

aletz Apr. 29 at 7:22 PM

$SNGX pretty much spot on

1 · Reply

ieatbaguette Apr. 29 at 6:03 PM

$SNGX I believe all buys under 35c will be rewarded

2 · Reply

GreedyGopher Apr. 29 at 4:26 PM

$SNGX Since its founding in 2007, SNGX has brought exactly 0 products to market... In recent years, three(3) 1 for 15 reverse splits followed by mass dilution. If you had 1000 shares in 2021 you now have 4 shares..... But you have it all figured out. This time is different......RIIIIGHT.👍🏿

1 · Reply

ieatbaguette Apr. 29 at 4:21 PM

$SNGX over reaction

0 · Reply

GreedyGopher Apr. 29 at 4:17 PM

$SNGX 🤣🤣🤣 Dont worry, I'll check back with you in 6 months to see how this investment turned out for you... mi)) just sit back with my popcorn

0 · Reply

Uc78612 Apr. 29 at 3:59 PM

$SNGX your buddies are getting ready to cover and will leave you hanging small fry

0 · Reply

GreedyGopher Apr. 29 at 3:58 PM

$SNGX 😳 🤣🤣🤣🤣🤣🤣🤣🤣🤣

1 · Reply

Uc78612 Apr. 29 at 3:43 PM

$SNGX loading up down here overreaction

0 · Reply

Go_Stop Apr. 29 at 10:32 AM

$SNGX He looks so normal, but he’s a total scammer. ??

0 · Reply

StocktwitsNews Apr. 29 at 3:15 AM

LCID, SNGX, SRAD Stock Hit 52-Week Lows Today: What's Driving The Selloff? $LCID $SNGX $SRAD https://stocktwits.com/news/equity/markets/why-lcid-sngx-srad-stocks-hit-52-week-lows-today/cZBq8xRRe33

0 · Reply

lecorb Apr. 28 at 11:43 PM

$HTCO $SNGX $VISN $AREB Big Crabs!

0 · Reply

GreedyGopher Apr. 28 at 10:59 PM

$SNGX i predict TWO 1 for 15 reverse splits in the next 14 months, each followed by massive dilution.... .. ...if they dont get delisted first.......Same old shit ive seen the last 6 years.....They have NEVER brought ANYTHING to market and never will.....

0 · Reply

Market Cap	3.56M
Revenue (ttm)	0.00
Net Income (ttm)	-11.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	928,700
Avg Vol	670,766
Day's Range	N/A - N/A
Shares Out	10.31M
Stochastic %K	3%
Beta	1.93
Analysts	Strong Buy
Price Target	$15.00